335 related articles for article (PubMed ID: 16103877)
21. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
Vega MI; Martinez-Paniagua M; Jazirehi AR; Huerta-Yepez S; Umezawa K; Martinez-Maza O; Bonavida B
Leuk Lymphoma; 2008 Oct; 49(10):1982-94. PubMed ID: 18949621
[TBL] [Abstract][Full Text] [Related]
22. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.
Stel AJ; Ten Cate B; Jacobs S; Kok JW; Spierings DC; Dondorff M; Helfrich W; Kluin-Nelemans HC; de Leij LF; Withoff S; Kroesen BJ
J Immunol; 2007 Feb; 178(4):2287-95. PubMed ID: 17277134
[TBL] [Abstract][Full Text] [Related]
23. Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.
Vega GG; Franco-Cea LA; Huerta-Yepez S; Mayani H; Morrison SL; Bonavida B; Vega MI
Int J Oncol; 2015 Nov; 47(5):1735-48. PubMed ID: 26398317
[TBL] [Abstract][Full Text] [Related]
24. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
Alas S; Emmanouilides C; Bonavida B
Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation.
Hongo F; Garban H; Huerta-Yepez S; Vega M; Jazirehi AR; Mizutani Y; Miki T; Bonavida B
Biochem Biophys Res Commun; 2005 Oct; 336(2):692-701. PubMed ID: 16143308
[TBL] [Abstract][Full Text] [Related]
27. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
29. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
30. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
31. p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes.
Craxton A; Shu G; Graves JD; Saklatvala J; Krebs EG; Clark EA
J Immunol; 1998 Oct; 161(7):3225-36. PubMed ID: 9759836
[TBL] [Abstract][Full Text] [Related]
32. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.
Alas S; Bonavida B
Cancer Res; 2001 Jul; 61(13):5137-44. PubMed ID: 11431352
[TBL] [Abstract][Full Text] [Related]
33. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
34. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
Shan D; Ledbetter JA; Press OW
Cancer Immunol Immunother; 2000 Mar; 48(12):673-83. PubMed ID: 10752475
[TBL] [Abstract][Full Text] [Related]
35. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
36. [Preclinical study of apoptosis of B-NHL cell lines induced by anti-CD20 monoclonal antibody].
Zhang HY; Chen HT; Guan ZZ; Huang Y; Zhang X; Lin TY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):883-7. PubMed ID: 19698222
[TBL] [Abstract][Full Text] [Related]
37. CD20-induced B cell death can bypass mitochondria and caspase activation.
van der Kolk LE; Evers LM; Omene C; Lens SM; Lederman S; van Lier RA; van Oers MH; Eldering E
Leukemia; 2002 Sep; 16(9):1735-44. PubMed ID: 12200688
[TBL] [Abstract][Full Text] [Related]
38. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
Pedersen IM; Buhl AM; Klausen P; Geisler CH; Jurlander J
Blood; 2002 Feb; 99(4):1314-9. PubMed ID: 11830481
[TBL] [Abstract][Full Text] [Related]
39. TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.
Kawabata KC; Ehata S; Komuro A; Takeuchi K; Miyazono K
Oncogene; 2013 Apr; 32(16):2096-106. PubMed ID: 22665052
[TBL] [Abstract][Full Text] [Related]
40. p38 mitogen-activated protein kinase and nuclear factor-κB facilitate CD40-mediated salivary epithelial cell death.
Ping L; Ogawa N; Zhang Y; Sugai S; Masaki Y; Weiguo X
J Rheumatol; 2012 Jun; 39(6):1256-64. PubMed ID: 22505709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
